» Articles » PMID: 25653589

Mitochondrial Protection by the Mixed Muscarinic/σ1 Ligand ANAVEX2-73, a Tetrahydrofuran Derivative, in Aβ25-35 Peptide-injected Mice, a Nontransgenic Alzheimer's Disease Model

Overview
Specialty Cell Biology
Date 2015 Feb 6
PMID 25653589
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD), the most prevalent dementia in the elderly, is characterized by progressive synaptic and neuronal loss. Mitochondrial dysfunctions have been consistently reported as an early event in AD and appear before Aβ deposition and memory decline. In order to define a new neuroprotectant strategy in AD targeting mitochondrial alterations, we develop tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (ANAVEX2-73, AE37), a mixed muscarinic receptor ligand and a sigma-1 receptor (σ1R) agonist. We previously reported that ANAVEX2-73 shows anti-amnesic and neuroprotective activities in mice injected intracerebroventricular (ICV) with oligomeric amyloid-β25-35 peptide (Aβ25-35). The σ1R is present at mitochondria-associated endoplasmic reticulum (ER) membranes, where it acts as a sensor/modulator of ER stress responses and local Ca(2+) exchanges with the mitochondria. We therefore evaluated the effect of ANAVEX2-73 and PRE-084, a reference σ1R agonist, on preservation of mitochondrial integrity in Aβ25-35-injected mice. In isolated mitochondria from hippocampus preparations of Aβ25-35 injected animals, we measured respiration rates, complex activities, lipid peroxidation, Bax/Bcl-2 ratios and cytochrome c release into the cytosol. Five days after Aβ25-35 injection, mitochondrial respiration in mouse hippocampus was altered. ANAVEX2-73 (0.01-1 mg/kg IP) restored normal respiration and PRE-084 (0.5-1 mg/kg IP) increased respiration rates. Both compounds prevented Aβ25-35-induced increases in lipid peroxidation levels, Bax/Bcl-2 ratio and cytochrome c release into the cytosol, all indicators of increased toxicity. ANAVEX2-73 and PRE-084 efficiently prevented the mitochondrial respiratory dysfunction and resulting oxidative stress and apoptosis. The σ1R, targeted selectively or non-selectively, therefore appears as a valuable target for protection against mitochondrial damages in AD.

Citing Articles

Mitochondrial pathways of copper neurotoxicity: focus on mitochondrial dynamics and mitophagy.

Aschner M, Skalny A, Lu R, Martins A, Tizabi Y, Nekhoroshev S Front Mol Neurosci. 2024; 17:1504802.

PMID: 39703721 PMC: 11655512. DOI: 10.3389/fnmol.2024.1504802.


Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the chaperone protein.

Garcia-Pupo L, Crouzier L, Bencomo-Martinez A, Meunier J, Morilleau A, Delprat B Acta Pharm Sin B. 2024; 14(10):4345-4359.

PMID: 39525570 PMC: 11544189. DOI: 10.1016/j.apsb.2024.06.013.


The selective butyrylcholinesterase inhibitor UW-MD-95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease.

Carles A, Hoffmann M, Scheiner M, Crouzier L, Bertrand-Gaday C, Chatonnet A CNS Neurosci Ther. 2024; 30(6):e14814.

PMID: 38887858 PMC: 11183908. DOI: 10.1111/cns.14814.


N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer's disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk.

Cheng D, Lei Z, Chu K, Lam O, Chiang C, Zhang Z Alzheimers Res Ther. 2024; 16(1):95.

PMID: 38693554 PMC: 11061967. DOI: 10.1186/s13195-024-01462-3.


Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer's Disease.

Guiselin T, Lecoutey C, Rochais C, Dallemagne P Pharmaceutics. 2023; 15(10).

PMID: 37896142 PMC: 10610275. DOI: 10.3390/pharmaceutics15102382.


References
1.
Rhein V, Song X, Wiesner A, Ittner L, Baysang G, Meier F . Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A. 2009; 106(47):20057-62. PMC: 2774257. DOI: 10.1073/pnas.0905529106. View

2.
Yang J, Liu X, Bhalla K, Kim C, Ibrado A, Cai J . Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997; 275(5303):1129-32. DOI: 10.1126/science.275.5303.1129. View

3.
Delobette S, Privat A, Maurice T . In vitro aggregation facilities beta-amyloid peptide-(25-35)-induced amnesia in the rat. Eur J Pharmacol. 1997; 319(1):1-4. DOI: 10.1016/s0014-2999(96)00922-3. View

4.
Liu X, Kim C, Yang J, Jemmerson R, Wang X . Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996; 86(1):147-57. DOI: 10.1016/s0092-8674(00)80085-9. View

5.
Mosconi L, Pupi A, de Leon M . Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci. 2008; 1147:180-95. PMC: 2661241. DOI: 10.1196/annals.1427.007. View